Sarepta Therapeutics (NASDAQ:SRPT) shares plummeted on Friday following reports of a third patient death linked to its gene ...

The death will likely further stoke safety concerns around Sarepta's gene therapies, as well as raise questions around the ...

A third patient has died from acute liver failure after receiving a gene therapy treatment from Sarepta Therapeutics, the biotech company confirmed to Bloomberg on July 18. The patient died while ...

Thirty-three states, the District of Columbia, and Puerto Rico will participate in CMS’ voluntary Cell and Gene Therapy (CGT) ...

Sarepta stock crashed Friday — wiping out all of its restructuring-tied gains — after a third recipient of one of its gene therapies died.

According to multiple reports, a 51-year-old man with limb-girdle muscular dystrophy died from acute liver failure after ...

A third patient has died this year after getting a gene therapy from Sarepta Therapeutics Inc., raising questions about the ...

The Purdy family shares their insights on navigating their child’s rare neurodegenerative disease and their direct ...

In a surprise, a FDA advisory panel voted that risks tied to a GSK blood cancer drug called Blenrep outweighed the benefits ...

Discover how Genome Valley is emerging as an essential partner in global biopharma and how it is now venturing into cell and gene therapy.

The patient, who was being treated with an investigational gene therapy for limb-girdle muscular dystrophy, died of acute ...

Lab study findings increase understanding of the molecular mechanisms underpinning vitamin D deficiency and highlight SDR42E1 ...